<DOC>
	<DOCNO>NCT00000832</DOCNO>
	<brief_summary>To determine safety immunogenicity rgp120/HIV-1SF2 combine MF59 adjuvant emulsion versus MF59 alone HIV-negative volunteer . One approach improve immunogenicity HIV-1 subunit protein vaccine combine immunogen adjuvant .</brief_summary>
	<brief_title>A Randomized , Placebo-Controlled , Double-Blinded Phase I Safety Immunogenicity Trial Recombinant Envelope Protein , HIV-1 SF-2 rgp120 ( BIOCINE ) , Combined With MF59 HIV-1 Uninfected Adult Volunteers</brief_title>
	<detailed_description>One approach improve immunogenicity HIV-1 subunit protein vaccine combine immunogen adjuvant . Healthy volunteer receive intramuscular injection rgp120/HIV-1SF2 MF59 adjuvant emulsion MF59 alone month 0 , 1 , 6 , 9 , 10 12 ( month 0 , 1 , 6 10 , amend 12/19/96 ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Inclusion Criteria Volunteers must : Normal history physical exam . HIV negativity . Absolute CD4 count &gt; = 400 cells/mm3 . Normal urine dipstick esterase nitrite . Lower risk sexual behavior . Exclusion Criteria Coexisting Condition : Subjects follow symptoms condition exclude : Positive hepatitis B surface antigen . Medical psychiatric condition ( recent suicidal ideation present psychosis ) preclude compliance . Active syphilis . NOTE : Subjects serology document false positive due remote ( &gt; 6 month ) treat infection eligible . Active tuberculosis . NOTE : Subjects positive PPD normal chest xray show evidence TB require isoniazid therapy eligible . Subjects follow prior condition exclude : History immunodeficiency , chronic illness , autoimmune disease , use immunosuppressive medication . History anaphylaxis serious adverse reaction vaccine . History serious allergic reaction substance , require hospitalization emergent medical care ( e.g. , StevensJohnson syndrome , bronchospasm , hypotension ) . Prior psychiatric condition ( history suicide attempt past psychosis ) preclude compliance . History cancer unless surgical excision consider achieved cure . Prior Medication : Excluded : Live attenuate vaccine within 60 day prior study entry . NOTE : Medically indicate kill subunit vaccine ( e.g. , influenza , pneumococcal ) exclude administer least 2 week HIV immunization . Experimental agent within 30 day prior study entry . Prior HIV vaccine . Prior Treatment : Excluded : Blood product immunoglobulin within past 6 month . Identifiable highrisk behavior HIV infection , include : History injection drug use within past 12 month . Higher risk sexual behavior .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>